Analytical methods for assay of ellagic acid and its solubility studies

Bala, Indu; Bhardwaj, V.; Hariharan, S.; Kumar, M. N. V. Ravi

doi:10.1016/j.jpba.2005.07.006

Cited by 197 publications

(151 citation statements)

References 14 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Solubility studies conducted by Bala et al, (2005) demonstrated that Ellagic acid was soluble in various pharmaceutically acceptable solvents including triethanolamine, polyethylene glycol 400 and N-methyl pyrrollidone (NMP). Ellagic acid showed poor solublity in water (9.7µg/mL) and due to its acidic nature it is soluble in phosphate buffer while, highly soluble in methanol [59] . Ellagic acid is Mehan S et al Ellagic acid at the cross roads of neurodegenerations 142 …”

Section: Polyphenol Ellagic Acid-targeting To Brain: a Hidden Treasurementioning

confidence: 99%

Polyphenol Ellagic Acid-Targeting To Brain: A Hidden Treasure

Mehan¹,

Kaur²,

Parveen³

et al. 2015

International Journal of Neurology Research

View full text Add to dashboard Cite

Alzheimer's disease is a severe neurodegenerative disorder that gradually results in loss of memory and impairment of cognitive functions in the elderly.Thedeposition of amyloid plaques is the primary event that leads to an oxidative and inflammatory reactions, neurofibrillary tangle formation, and ultimately neuronal death. The most prominent losses occur with cholinergic neurons that plays an important role in the formation of memory and cognitive functions. Insulin receptor numbers also altered, thusglucosemetabolism is defected in AD. Polyphenol ellagic acid (EA) possesses antioxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and cardioprotection activities.Activities of EA that are linked with protection of neuronal abnormalities like anti-depressant, antianxiety, anti-nociception. Ellagic acid inhibits β-secretase enzymatic activities, thus prevents the main pathologic hallmark of AD. There are varieties of herbal extracts and phytochemicals formulations extensively used to provide symptomatic relief to AD patients. Together these results our hypothesis that EA may prevent the neuronal dysfunctions as well as further work is also required to examine the pharmacological properties of EA in the protection of specially neurodegenerative disorder like AD. Here, we discuss how we can use the knowledge to improve treatment strategies of EA in AD and to explore the various signaling pathways involved in the progression of neuronal death.

show abstract

Section: Polyphenol Ellagic Acid-targeting To Brain: a Hidden Treasurementioning

confidence: 99%

Polyphenol Ellagic Acid-Targeting To Brain: A Hidden Treasure

Mehan¹,

Kaur²,

Parveen³

et al. 2015

International Journal of Neurology Research

View full text Add to dashboard Cite

show abstract

“…Solubilities of the two compounds were determined as described before (Bala et al, 2006). A supersaturated solution of TP-58 (TP-67) was made.…”

Section: Determination Of the Solubilitymentioning

confidence: 99%

Preparation of the thienopyridine derivatives loaded liposomes and study on the effect of compound-lipid interaction on release behavior

Liu

Tang²,

et al. 2012

Drug Delivery

View full text Add to dashboard Cite

“…EA was reported to inhibit cell proliferation and cell cycle progression of bladder (6), colorectal (7), and breast cancer (8). In spite of EAs benefits, the poor water solubility (9.7 µg/mL at pH 7.4) and extensive first pass intestinal and hepatic metabolisms and, consequently, low oral bioavailability of EA have limited the therapeutic potential of the molecule to mature into clinical trials (9,10). In order to improve its therapeutic value, it is proposed to employ a nanoparticulate delivery system.…”

Section: Introductionmentioning

confidence: 99%

Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles (SLNs)

et al. 2018

View full text Add to dashboard Cite

Background: Ellagic acid (EA) is a polyphenol, whose anti-cancer properties have been demonstrated in several cancer studies, but the poor water solubility and low bioavailability have limited its therapeutic potential. Objectives: The present study proposed to develop solid lipid nanoparticles (SLNs) as a delivery system for improving the anticancer capability of EA on prostate cancer cell line. Methods: EA-loaded SLNs were prepared by hot homogenization technique and characterized by different techniques. Cytotoxicity of EA and EA-loaded SLNs on prostate cancer cell line (PC3) was evaluated by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay, and nucleus condensation, or chromatin fragmentation (the signs of apoptosis) were studied by 4'-6-diamidino-2-phenylindole (DAPI) staining. The expression of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax), which are involved in apoptosis, were evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results:The nanoparticles with appropriate characteristics (particle size of 96 nm and Encapsulation Efficiency of 88%) were prepared. The in vitro drug release profile showed a burst release in the first hours and followed by a sustained EA release until 72 hours. EA-loaded SLNs displayed a good stability for 4 weeks of storage at 4 -8°C. Cytotoxicity evaluations demonstrated that EA-loaded SLNs prevented prostate cancer cells growth in a low IC50 value compared to the EA. The results of qRT-PCR demonstrated that EA causes up-regulation of Bax and this regulation intensified when EA was loaded into SLNs, but there was no punctual correlation between the EA and EA-loaded SLNs in down-regulation of Bcl-2. Conclusions:The results strengthen our hope that loading EA into SLNs could possibly overcome the therapeutic limitations of EA and make it more effective in prostate cancer therapy.

show abstract

Analytical methods for assay of ellagic acid and its solubility studies

Cited by 197 publications

References 14 publications

Polyphenol Ellagic Acid-Targeting To Brain: A Hidden Treasure

Polyphenol Ellagic Acid-Targeting To Brain: A Hidden Treasure

Preparation of the thienopyridine derivatives loaded liposomes and study on the effect of compound-lipid interaction on release behavior

Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles (SLNs)

Contact Info

Product

Resources

About